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Abstract 
Background: Statins suppress the progression of atherosclerosis by reducing low-density lipoprotein (LDL) choles-
terol levels. Pemafibrate (K-877), a novel selective peroxisome proliferator-activated receptor α modulator, is expected 
to reduce residual risk factors including high triglycerides (TGs) and low high-density lipoprotein (HDL) cholesterol 
during statin treatment. However, it is not known if statin therapy with add-on pemafibrate improves the progression 
of atherosclerosis. The aim of this study was to assess the effect of combination therapy with pitavastatin and pemafi-
brate on lipid profiles and endothelial dysfunction in hypertension and insulin resistance model rats.
Methods: Seven-week-old male Dahl salt-sensitive (DS) rats were divided into the following five treatment groups 
(normal diet (ND) plus vehicle, high-salt and high-fat diet (HD) plus vehicle, HD plus pitavastatin (0.3 mg/kg/day), HD 
plus pemafibrate (K-877) (0.5 mg/kg/day), and HD plus combination of pitavastatin and pemafibrate) and treated 
for 12 weeks. At 19 weeks, endothelium-dependent relaxation of the thoracic aorta in response to acetylcholine was 
evaluated.
Results: After feeding for 12 weeks, systolic blood pressure and plasma levels of total cholesterol were significantly 
higher in the HD-vehicle group compared with the ND-vehicle group. Combination therapy with pitavastatin and 
pemafibrate significantly reduced systolic blood pressure, TG levels, including total, chylomicron (CM), very LDL 
(VLDL), HDL-TG, and cholesterol levels, including total, CM, VLDL, and LDL-cholesterol, compared with vehicle treat-
ment. Acetylcholine caused concentration-dependent relaxation of thoracic aorta rings that were pre-contracted 
with phenylephrine in all rats. Relaxation rates in the HD-vehicle group were significantly lower compared with 
the ND-vehicle group. Relaxation rates in the HD-combination of pitavastatin and pemafibrate group significantly 
increased compared with the HD-vehicle group, although neither medication alone ameliorated relaxation rates sig-
nificantly. Western blotting experiments showed increased phosphorylated endothelial nitric oxide synthase protein 
expression in aortas from rats in the HD-pemafibrate group and the HD-combination group compared with the HD-
vehicle group. However, the expression levels did not respond significantly to pitavastatin alone.
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Background
Many clinical trials and meta-analyses have revealed 
that treatment with statins, which are 3-hydroxy-meth-
ylglutaryl coenzyme A (HMG-CoA) reductase inhibi-
tors, targets a reduction in low-density lipoprotein 
cholesterol (LDL-C) and thereby decreases the risk of 
coronary heart disease (CHD) and all-cause mortal-
ity [1]. However, many CHD cases are not prevented 
and the residual risk factors including high triglycer-
ide (TG) and low high-density lipoprotein cholesterol 
(HDL-C) levels remain unsettled [2].
Fasting and non-fasting hypertriglyceridemia is a 
risk factor for CHD [3–5]. Several mechanisms of 
atherogenesis in hypertriglyceridemia are proposed. 
Hypertriglyceridemia is involved in the production of 
proinflammatory cytokines, recruitment of neutro-
phils, and generation of oxidative stress, resulting in 
endothelial dysfunction [6–9]. Endothelial dysfunction 
is an initial process of atherogenesis, and it contrib-
utes to the pathogenesis of CHD. Among TG-rich lipo-
proteins, remnant lipoproteins depress the activity of 
endothelial nitric oxide synthase (eNOS) in endothelial 
cells and decrease nitric oxide (NO) released from the 
endothelium [10, 11].
Endothelial dysfunction assessed by brachial artery 
flow-mediated dilatation (FMD) has been shown to 
be impaired in patients with traditional coronary risk 
factors, including hypertension, dyslipidemia, diabetes 
mellitus, and smoking, and it has been considered to be 
a cause of atherosclerosis [5, 6, 12–14]. Statins improve 
endothelial function as assessed by FMD [15, 16]. In 
addition, hypertriglyceridemia is independently associ-
ated with endothelial dysfunction as assessed by FMD 
in patients with CHD during statin therapy [17].
Previously, a clinical trial for combination therapy 
with a statin plus a fibrate to reduce the residual risk 
was conducted in patients with type 2 diabetes mellitus. 
The ACCORD study showed that combination therapy 
with simvastatin plus fenofibrate did not reduce car-
diovascular outcomes and mortality compared with 
simvastatin alone [18]. However, in a preplanned sub-
group analysis, there was a trend benefit of fenofibrate 
in patients with a high TG level (≥ 204 mg/dL) or a low 
HDL-C level (≤ 34  mg/dL) [2]. Additionally, fibrate 
treatment during the trial period was associated with 
a legacy effect of improved survival over a post-trial 
follow-up [19]. These findings suggest that re-evalua-
tion of TG-lowering therapy as an add-on strategy to 
statins is needed.
Fibrates activate a transcription factor that belongs to 
the nuclear receptor superfamily, peroxisome prolifer-
ator-activated receptor α (PPARα), and controls lipid 
metabolism. Recently, pemafibrate (K-877), a novel selec-
tive PPARα modulator (SPPARMα), has been developed 
[20], which is even more potent than fenofibric acid (the 
active metabolite of fenofibrate) and more specific for 
human PPARα than either PPARγ or δ [21].
Pemafibrate robustly decreases serum TG levels in fast-
ing and non-fasting or postprandial states and increases 
serum HDL-C levels [22, 23]. Moreover, pemafibrate 
was superior to fenofibrate in terms of serum TG-low-
ering effect and hepatic and renal safety [22]. The ongo-
ing PROMINENT trial is ongoing in patients with type 2 
diabetes mellitus, elevated TG, and low levels of HDL-C 
to determine whether treatment with pemafibrate safely 
reduces residual cardiovascular risk. Therefore, we 
hypothesized that combination therapy with a statin plus 
pemafibrate could notably improve endothelial dysfunc-
tion in metabolic syndrome. The aim of this study was to 
assess the effect of combination therapy with pitavasta-
tin and pemafibrate on lipid profiles and endothelial dys-
function in Dahl salt-sensitive (DS) rats fed a high-salt 




Seven-week-old male Dahl salt-sensitive (DS) rats 
(n = 44) (Japan SLC, Shizuoka, Japan) were fed a normal 
diet (ND; 0.3% NaCl and 4.5% fat) (CE-2, CLEA Japan, 
Inc., Tokyo, Japan) or a high-salt and high-fat diet (HD; 
8% NaCl and 29.4% fat) (CLEA Japan), as previously 
described [26], and they were treated with a vehicle (0.5% 
carboxy methyl cellulose and 0.5% methyl cellulose), pita-
vastatin (0.3 mg/kg/day) (Kowa Co., Ltd., Tokyo, Japan), 
pemafibrate (K-877) (0.5  mg/kg/day) (Kowa Co., Ltd.) 
or a combination of pitavastatin (0.3  mg/kg/day) and 
pemafibrate (K-877) (0.5 mg/kg/day) (Fig. 1) by oral gav-
age for a period of 12  weeks (Fig.  1). Body weight was 
measured once a week for a period of 12  weeks. Rats 
were divided into the following five groups: (1) ND-
vehicle group (n = 5) fed an ND and treated with vehicle; 
Conclusions: Combination therapy with pitavastatin and pemafibrate improved lipid profiles and endothelial dys-
function in hypertension and insulin resistance model rats. Pemafibrate as an add-on strategy to statins may be useful 
for preventing atherosclerosis progression.
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(2) HD-vehicle group (n = 9) fed an HD and treated with 
vehicle; (3) HD-pitavastatin group (n = 10) fed an HD 
and treated with pitavastatin; (4) HD-pemafibrate group 
(n = 10) fed an HD and treated with pemafibrate; and (5) 
HD-combination group (n = 10) fed an HD and treated 
with combination of pitavastatin and pemafibrate. All 
experimental protocols were approved by and conducted 
in accordance with the recommendations of the Okay-
ama University Animal Care and Use Committee (permit 
number OKU-2019349).
Blood pressure and pulse rate measurement
Systolic blood pressure and pulse rate were measured 
at 12 and 19  weeks using a tail-cuff plethysmography 
(MK-2000 Muromachi, Tokyo, Japan or BP-2000, Vis-
itech Systems, Inc., Apex, NC, USA). An average of three 
measurements was used.
Blood collection and measurements
At 19 weeks, rats were anesthetized with isoflurane. Non-
fasting whole blood was collected from the abdominal 
aorta into a chilled tube. After centrifugation at 3000×g 
for 10  min at 4  °C, plasma was collected and stored at 
−80  °C. Plasma total bilirubin was measured using the 
vanadate oxidase method. Plasma glucose was measured 
using the hexokinase/glucose-6-phosphate dehydro-
genase method. Plasma cholesterol and TG content in 
lipoprotein fractions including chylomicron (CM), very 
low-density lipoprotein (VLDL), LDL, and HDL were 
analyzed using high-performance liquid chromatography 
by Skylight Biotech (Akita, Japan), as described [27, 28].
Vascular relaxation studies
Endothelium-dependent relaxation in response to ace-
tylcholine was evaluated. At 19 weeks, rats were anes-
thetized with isoflurane. The thoracic aorta was rapidly 
removed, gently cleaned taking care not to damage the 
endothelium, and it was cut into 3-mm rings. The rings 
were then cut open. Open aortic rings were placed in 
a 10-mL organ bath containing Krebs–Henseleit solu-
tion (KHS; in mmol/L: 118 NaCl, 4.7 KCl, 2.5  CaCl2, 1.2 
 KH2PO4, 1.2  MgSO4, 25  NaHCO3, 11.1 glucose). One 
end of the open ring was connected to a tissue holder 
and the other end was connected to a force displace-
ment transducer (AD-611  J, Nihon Kohden, Tokyo, 
Japan). The bathing solution was gassed with 95%  O2 
and 5%  CO2 at 37  °C (pH 7.4). The tissue was equili-
brated for 60 min under a resting tension of 1 g. During 
this time, Krebs–Henseleit solution was replaced every 
15  min with fresh solution. The tissues were pre-con-
tracted with phenylephrine (0.3  µmol/L). Tissues were 
then re-washed and pre-contracted with phenylephrine 
(0.3 µmol/L). After the phenylephrine-induced contrac-
tion had reached a plateau, the concentration–response 
relationships for acetylcholine (1–10,000 nmol/L) were 
obtained by adding acetylcholine to the bath in a cumu-
lative manner. Finally, papaverine (100 µmol/L) relaxa-
tion responses were obtained. The relaxation responses 
obtained were expressed as a percentage of the maximal 
relaxation that was evoked by papaverine (100 µmol/L).
Western blot analysis
Protein samples from the abdominal aortas of 4 or 6 
randomly selected rats in each group were prepared 
using a BEAD crusher (µT-12, Taitec, Koshigaya, Japan). 
Tissue lysates were extracted in radioimmunoprecipi-
tation (RIPA) buffer with 2  mmol/L phenylmethylsul-
fonyl fluoride, 1  mmol/L sodium orthovanadate, and 
10 mmol/L sodium fluoride (sc-24948, Santa Cruz, Dal-
las, Texas, USA) and 20 µg of lysates was subjected to 
SDS-PAGE. Rabbit anti-eNOS antibody (#610297, BD 
Biosciences, Franklin lakes, New Jersey, USA), rab-
bit anti-phospho-eNOS (Ser1177) antibody (#612393, 
BD Biosciences, Franklin lakes, New Jersey, USA), and 
mouse anti-beta actin antibody (ab6276, Abcam, Cam-
bridge, UK) were used. All primary antibodies were 
used at a dilution of 1:1000. The second antibody was 
horseradish peroxidase-conjugated anti-rabbit or anti-
mouse IgG antibody (NA934 and NA931, GE Health-
care Bio-Sciences, Buckinghamshire, England). Positive 
signals were detected using a chemiluminescence sys-
tem (ECL plus, GE Healthcare Bio-Sciences).
Vehicle
Normal diet (0.3% NaCl and 4.5% fat)
Vehicle











Fig. 1 Scheme of experimental protocol. We used 7-week-old male 
Dahl salt-sensitive rats. Rats were fed a normal diet (ND) (0.3% NaCl 
and 4.5% fat) or a high-salt and high-fat diet (HD) (8% NaCl and 29.4% 
fat). The rats were divided into five different groups and treated 
with vehicle, pitavastatin (0.3 mg/kg), pemafibrate (K-877) (0.5 mg/
kg), or a combination of pitavastatin (0.3 mg/kg) and pemafibrate 
(K-877) (0.5 mg/kg) for 12 weeks. At 19 weeks, blood collection and 
evaluation of endothelium-dependent relaxations of thoracic aorta 
were performed
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Quantitative real‑time polymerase chain reaction (qPCR) 
analysis
For reverse transcription (RT)- PCR analysis, RNA was 
extracted from the abdominal aortas of 4 or 6 randomly 
selected rats in each group with RNeasy Mini Kit (Qia-
gen). The total RNA (2 μg) from each tissue sample was 
used to generate complementary DNA (cDNA) with 
ReverTra Ace (TOYOBO, Osaka, Japan). The cDNA was 
subjected to PCR with TaqMan Gene Expression Master 
Mix (Applied Biosystems, Foster City, CA, USA) and pre-
designed gene specific primer and probe sets (TaqMan 
Gene Expresso in Assays; Applied Biosystems). Quantita-
tive real-time PCR was performed using the Applied Bio-
systems 7300 realtime PCR System (Applied Biosystems). 
The PCR primers used were the following: NADPH oxi-
dase-4 (NOX4), Rn00585380 and actin beta (ACTB), 
Rn00667869. ACTB was used as the internal control.
Statistical analysis
Statistical analysis was performed using SPSS version 
24 (IBM, New York, USA). All results are expressed as 
the mean ± standard deviation (SD). For comparison 
between different treatment groups, statistical analy-
sis was performed using a one-way analysis of variance 
(ANOVA) with a Bonferroni post hoc test. Vascular 
relaxation studies were analyzed using a mixed effect 
model with a Bonferroni post hoc test. P-values < 0.05 
were considered to be significant.
Results
Effects of pitavastatin, pemafibrate, or a combination 
of pitavastatin and pemafibrate on blood pressure 
and heart rate
After feeding for 12  weeks, systolic blood pressure was 
significantly higher in the HD-vehicle group compared 
with the ND-vehicle group (Table 1). After treatment for 
12 weeks, systolic blood pressure was significantly lower 
in the HD-combination group compared with the HD-
vehicle group, the HD-pitavastatin group, and the HD-
pemafibrate group (Table 1). We observed no difference 
in heart rate among the five groups at 12  weeks post-
feeding of ND or HD and treatment.
Effects of pitavastatin, pemafibrate, or a combination 
of pitavastatin and pemafibrate on blood measurements
After feeding for 12 weeks, plasma levels of total choles-
terol were significantly higher in the HD-vehicle group 
compared with the ND-vehicle group (Fig. 2a). For lipo-
protein fractions, plasma LDL-cholesterol and HDL-cho-
lesterol levels were significantly higher in the HD-vehicle 
group compared with the ND-vehicle group (Fig. 2c–e).
Treatment with pemafibrate and a combination of pita-
vastatin and pemafibrate significantly reduced plasma 
total cholesterol levels compared with vehicle treatment 
(Fig.  2a). For lipoprotein fractions, plasma CM-choles-
terol, VLDL-cholesterol, and LDL-cholesterol levels were 
significantly lower in the HD-combination group com-
pared with the HD-vehicle group (Fig.  2b–d). Plasma 
VLDL-cholesterol and LDL-cholesterol levels were also 
significantly lower in the HD-pemafibrate group com-
pared with the HD-vehicle group (Fig. 2c, d).
There were no significant differences in plasma total 
TG levels between the ND-vehicle group and the HD-
vehicle group at 12  weeks post-feeding in accordance 
with previous reports [24, 25] (Fig. 3a).
Treatment with pemafibrate and a combination of pita-
vastatin and pemafibrate significantly reduced plasma 
total TG levels compared with vehicle treatment (Fig. 3a). 
For lipoprotein fractions, plasma CM-TG, VLDL-TG, 
and HDL-TG levels were significantly lower in the 
Table 1 Effects of  pitavastatin, pemafibrate or  combination of  pitavastatin and  pemafibrate on  BP, HR and  blood 
measurements
Effects of pitavastatin, pemafibrate, or a combination of pitavastatin and pemafibrate on total and phospho-eNOS and NOX4 expression in the rat aorta
Values are mean ± SD. *P < 0.001 vs. ND-vehicle group. #P < 0.005 vs. HD-vehicle. §P < 0.001 vs. HD-pitavastatin group. †P < 0.01 vs. HD-pemafibrate group. ‡P < 0.005 
vs. HD-vehicle
BP blood pressure, ND normal diet, HD high-salt and high-fat diet, SBP systolic blood pressure, HR heart rate
Group ND‑vehicle HD‑vehicle HD‑pitavastatin HD‑pemafibrate HD-combination
Food ND HD HD HD HD
Treatment Vehicle Vehicle Pitavastatin Pemafibrate Combination
Number of rats 5 9 10 10 10
SBP (mmHg) 143 ± 2 194 ± 7* 197 ± 8 193 ± 8 179 ± 10*#§†
HR (beats/min) 376 ± 11 402 ± 37 383 ± 19 400 ± 24 383 ± 31
Blood measurements
 Total bilirubin (mg/dL) 0.01 ± 0.01 0.01 ± 0.01 0.03 ± 0.03 0.01 ± 0.01 0.02 ± 0.01
 Glucose (mg/dL) 241 ± 20 236 ± 30 232 ± 22 236 ± 15 228 ± 15
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HD-pemafibrate group and the HD-combination group 
compared with the HD-vehicle group (Fig. 3b, c, e).
There were no significant differences in plasma total 
bilirubin and plasma glucose levels among the five groups 
at 12 weeks post-feeding and treatment.
Effects of pitavastatin, pemafibrate, 
or a combination of pitavastatin and pemafibrate 
on endothelium‑dependent vascular relaxation 
in response to acetylcholine
Acetylcholine (1 − 10,000 nmol/L) caused concentration-
dependent relaxation in thoracic aorta rings that were 
pre-contracted by phenylephrine (0.3 µmol/L) in all five 
groups (Fig. 4). Relaxation rates in the HD-vehicle group 
were significantly lower compared with the ND-vehicle 
group. Relaxation rates in the HD-combination of pita-
vastatin and pemafibrate group significantly increased 
compared with those in the HD-vehicle group, although 
neither medication alone ameliorated relaxation rates 
significantly.
Western blotting experiments revealed that there was 
no significant difference in total eNOS protein expression 
between aortas from rats of HD-vehicle, HD-pitavastatin, 
HD-pemafibrate, and HD-combination groups (Fig.  5a, 
b). Expression levels of phospho-Ser1177 eNOS/total 
eNOS in the HD-pemafibrate group and the HD-com-
bination group were significantly increased compared 
to those in HD-vehicle group (HD-vehicle group versus 
HD-pemafibrate group, P < 0.05; and HD-vehicle group 
versus HD-combination group, P < 0.01; Fig. 5a, c). How-
ever, the expression levels did not respond significantly to 
pitavastatin alone.
We also investigated the expression levels of NOX4, 
an enzyme that produces superoxide and plays a pivotal 
role in generation of oxidative stress in vascular smooth 
muscle cells [29]. There were no significant differences in 
expression levels of NOX4 mRNA among the five groups 
(Fig. 5d).
Discussion
The major new finding of this work is that combination 
therapy with pitavastatin and pemafibrate can improve 
endothelial dysfunction in hypertension and insulin 














































































































Fig. 2 Effects of pitavastatin, pemafibrate, or a combination of pitavastatin and pemafibrate on plasma cholesterol profile. Rats were fed a normal 
diet (ND) or a high-salt and high-fat diet (HD). The rats were divided into five groups and treated with vehicle, pitavastatin, pemafibrate (K-877), or a 
combination of pitavastatin and pemafibrate. a Total cholesterol, b chylomicron (CM)-cholesterol, c very low-density lipoprotein (VLDL)-cholesterol, 
d low-density lipoprotein (LDL)-cholesterol, e high-density lipoprotein (HDL)-cholesterol. Data are expressed as the mean ± SD. Number of rats in 
each group: ND-vehicle, n = 5; HD-vehicle, n = 9; HD-pitavastatin, n = 10; HD-pemafibrate, n = 10; and HD-combination, n = 10. Statistical analysis 
was performed using a one-way ANOVA with a Bonferroni post hoc test
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ameliorated endothelial function significantly. Addition-
ally, combination therapy significantly reduced systolic 
blood pressure, TG levels including total, CM, VLDL, 
and HDL-TG, and cholesterol levels, including total, CM, 
VLDL, LDL-cholesterol, compared with vehicle treat-
ment and increased expression of phosphorylated eNOS 
proteins in aortas. These results are considered to be a 
possible cause of the beneficial effects of combination 
therapy on endothelial function.
A double-blind, placebo-controlled, phase 2 clinical 
trial revealed that pemafibrate decreased TG, VLDL-
cholesterol, CM-cholesterol, remnant lipoprotein cho-
lesterol, apolipoprotein B, and apolipoprotein C-III levels 
and increased levels of HDL-cholesterol levels in dyslipi-
demic patients with high TG and low HDL-cholesterol 
[30]. This study also showed that pemafibrate decreased 
TG, including total, CM, VLDL, and HDL-TG, and cho-
lesterol, including total, VLDL, and LDL, in dyslipidemic 
rats with high TG and high cholesterol levels. A recent 
meta-analysis also revealed that pemafibrate significantly 
reduced TG levels [31]. Takei et al. reported that pemafi-


























































































Fig. 3 Effects of pitavastatin, pemafibrate, or combination of pitavastatin and pemafibrate on plasma triglyceride profile. Rats were fed a normal 
diet (ND) or a high-salt and high-fat diet (HD). The rats were divided into five groups and treated with vehicle, pitavastatin, pemafibrate (K-877), 
or combination of pitavastatin and pemafibrate. a Total triglyceride (TG), b chylomicron (CM)-TG, c very low-density lipoprotein (VLDL)-TG, d 
low-density lipoprotein (LDL)-TG, e high-density lipoprotein (HDL)-TG. Data are expressed as the mean ± SD. Number of rats in each group: 
ND-vehicle, n = 5; HD-vehicle, n = 9; HD-pitavastatin, n = 10; HD-pemafibrate, n = 10; and HD-combination, n = 10. Statistical analysis was 


























Fig. 4 Effects of pitavastatin, pemafibrate or combination of 
pitavastatin and pemafibrate on endothelium-dependent vascular 
relaxations in response to acetylcholine. Rats were fed a normal diet 
(ND) or a high-salt and high-fat diet (HD). The rats were divided into 
five groups and treated with a vehicle, pitavastatin, pemafibrate 
(K-877), or combination of pitavastatin and pemafibrate. Data 
are expressed as the mean ± SD. *P < 0.001, HD-vehicle group 
versus ND-vehicle group.# P < 0.05, HD-combination group versus 
HD-vehicle group. Number of rats in each group: ND-vehicle, n = 4; 
HD-vehicle, n = 5; HD-pitavastatin, n = 5; HD-pemafibrate, n = 5; 
and HD-combination, n = 5. Statistical analysis was performed using 
mixed effect model with a Bonferroni post hoc test
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treat hyperlipidemia that works well in both the liver 
and small intestine of LDL receptor knockout  (Ldlr−/−) 
mice [32]. Sairyo et al. reported that pemafibrate (K-877) 
decreased intestinal mRNA expression of ApoB and 
Npc1l1 [33]. Our study also revealed that pemafibrate 
improved VLDL-TG and CM-TG, and thus, we presume 
that pemafibrate had beneficial effects on the liver and 
small intestine in our model. Because the model showed 
high HDL-cholesterol levels rather than low HDL-cho-
lesterol levels, pemafibrate did not increase the HDL-
cholesterol levels.
It is clinically known that pitavastatin lowers LDL 
cholesterol and increases HDL cholesterol and that 
pemafibrate lowers TG and increases HDL cholesterol. 
However, these effects were not observed in this study 
except for reductions in TG and VLDL-TG using Pemafi-
brate. HMG-CoA reductase inhibitors (statins) do not 
lower plasma cholesterol in rats [34]. In accordance with 
previous studies, pitavastatin did not reduce cholesterol 
levels significantly in this study with a rat model. Pemafi-
brate increased HDL cholesterol levels in mice [35], but 
our study showed that pemafibrate increased HDL cho-
lesterol levels in DS rats. These results needed to be con-
firmed in future studies. However, combination therapy 
with pitavastatin and pemafibrate significantly decreased 
TG levels, including total, CM, VLDL, and HDL-TG, and 
cholesterol levels, including total, CM, VLDL, and LDL, 
in dyslipidemic rats with high TG and high cholesterol. 
A double-blind, placebo-controlled clinical trial also 
revealed that pemafibrate add-on therapy in combination 
with pitavastatin treatment showed a robust reduction of 
TG in patients with dyslipidemia [36]. These results sup-
port the favorable effects of combination therapy on lipid 
profiles in dyslipidemic conditions.
Combination therapy with pitavastatin and pemafi-
brate significantly improved systolic blood pressure 
compared with vehicle treatment in salt-sensitive hyper-
tensive rats fed a high-salt and high-fat diet. Huang 
et  al. reported that endothelium-derived relaxing factor 
activity, as assayed by acetylcholine-induced relaxation, 
is absent in eNOS mutant mice and that eNOS mutant 
mice are hypertensive [37]. Therefore, increased expres-
sion of phospho-eNOS on Ser1177 proteins seems to 
be associated with improvement of blood pressure in 
this study. Saka et al. reported that treatment with pita-
vastatin (0.3  mg/kg/d) did not lower blood pressure 
and levels of TC and TG in DS rats, in accordance with 









































































Fig. 5 Effects of pitavastatin, pemafibrate, or combination of pitavastatin and pemafibrate on total and phospho-eNOS and NOX4 expression in 
the rat aorta. a Images of Western blot analysis of total and phospho-endothelial nitric oxide synthase (eNOS) in aorta from rats fed a high-salt 
and high-fat diet (HD). b Western blot analysis of total eNOS. c Western blot analysis of phospho-eNOS. d qPCR analysis of NOX4 mRNA. Data 
are presented relative to ND-vehicle and expressed as the mean ± SD. Number of rats in each group: ND-vehicle, n = 4; HD-vehicle, n = 6; 
HD-pitavastatin, n = 6; HD-pemafibrate, n = 6; and HD-combination, n = 6. Statistical analysis was performed using a one-way ANOVA with a 
Bonferroni post hoc test
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Wistar-Kyoto rats that received L-nitro-arginine methyl 
ester (L-NAME), a NOS inhibitor, showed a progressive 
increase in systolic arterial blood pressure and that treat-
ment with a high dose of pitavastatin (1 mg/kg/d) signifi-
cantly lowered blood pressure. However, levels of TC, TG 
and HDL cholesterol remained unchanged. Therefore, 
improvement of lipid profiles in combination therapy 
might not be involved in the effects of lowering blood 
pressure in our study [39]. Gilbert et  al. also reported 
that the PPARα agonist fenofibrate lowers blood pressure 
in salt-sensitive hypertensive patients [40]. The precise 
mechanism of this phenomenon remains unclear, and 
further studies are needed to clarify this point.
As for the dose of pemafibrate in animal experiments, 
Hennuyer et al. reported that pemafibrate at 0.1 mg/kg/
day and 1  mg/kg/day reduced plasma TC (−72% and 
−79% respectively) and TG (−68% and −85% respec-
tively) concentrations compared to the control in human 
apolipoprotein E2 knock-in (apoE2KI) mice fed a western 
diet [35]. Dong et al. reported that a high-fat diet reduced 
the expression of ATP-binding cassette transporter A1 
(ABCA1) in the mouse pancreas but that pemafibrate 
(K-877) treatment (0.3  mg/kg/day) increased ABCA1 
expression compared to that in high-fat diet-fed mice 
[41]. Therefore, we assumed that pemafibrate at 0.5 mg/
kg/day could improves lipid metabolism in an animal 
model fed a high-fat diet.
Increased expression of phospho-eNOS on Ser1177 
proteins was observed in aortas from rats in the HD-
combination group compared with those from rats from 
the HD-vehicle group. Because Ser1177 phosphoryla-
tion has been shown to increase NO production from 
eNOS [42], this reaction might have contributed to the 
improvement of endothelium-dependent relaxation of 
the aorta in response to acetylcholine using combination 
therapy. There were no significant differences in expres-
sion levels of NOX4 mRNA among the five groups. Other 
molecules or genes also need to be investigated in future 
studies.
Regarding the issue of statins and glucose level, Kim 
et al. reported that use of atorvastatin, rosuvastatin, pita-
vastatin and simvastatin had a significant association 
with increase in fasting glucose of non-diabetic individu-
als [43]. However, Jeong et al. reported that administra-
tion of highest-dose pitavastatin did not increase the risk 
of new-onset diabetes in patients at high risk of devel-
oping diabetes [44]. It has been shown that pemafibrate 
suppresses diet-induced obesity in mice and improves 
their obesity-related metabolic abnormalities includ-
ing glucose, insulin and TG levels [45]. We also showed 
that combination therapy of pitavastatin and pemafibrate 
did not increase glucose levels. Thus, combination ther-
apy of pitavastatin and pemafibrate can be safely used in 
patients with metabolic syndrome who are at a high risk 
of developing diabetes.
Study limitations
This study has several limitations. First, we only assessed 
the effects of combination therapy on endothelium-
dependent relaxation of the aorta in response to ace-
tylcholine. Other critical homeostatic roles of the 
endothelium were not assessed in this study. Second, this 
study was performed using Dahl salt-sensitive rats fed a 
high-salt and high-fat diet. This model shows hyperten-
sion, insulin resistance and endotherial dysfunction, but 
TG levels are not elevated. Therefore, we could not con-
firm the effects of an increase in TG-rich lipoproteins or 
remnant lipoproteins on endothelial dysfunction. Third, 
the sample size of the ND-vehicle group was smaller than 
the sample sizes of other groups for a financial reason. 
Further studies are needed to clarify these points.
Conclusions
Combination therapy with pitavastatin and pemafibrate 
improved lipid profiles including TG and cholesterol lev-
els and ameliorated endothelial dysfunction. There was 
also an increase in the expression level of phospho-eNOS 
on Ser1177 protein in hypertension and insulin resistance 
model rats. Pemafibrate as an add-on strategy to statins 
may be useful for preventing atherosclerosis progression.
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